

# **ICAO Roundtable**


## **Reopening Borders and Building Trust**

**YY Teo**  
**Professor, Dean**  
**Saw Swee Hock School of Public Health**

*Turning Discovery into Healthier Communities*

# COVID-19 on Aviation

## Estimated impact on international passenger traffic and revenue for 2020



Source: ICAO estimates

# Europe: A caution against open borders?


## LOCKDOWNS & CURFEWS IN EUROPE

■ National Lockdown

■ Local Lockdown

○ National Curfews

□ Local Curfews



- Fallacy of COVID-19 vaccine as silver bullet for aviation sector and border reopening
- Global considerations around:
  - Vaccine **Efficacy**
  - Vaccine **Durability/Frequency**
  - Vaccine **Uptake**

**How do (some) countries  
decide on reopening borders  
without relying on  
a global uptake of an effective  
COVID-19 vaccine?**

Royal Society DELVE Initiative

[About](#) [Addenda](#) [Blog](#) [Data & Software](#) [Media](#) [People](#) [Reports](#)

[\[edit\]](#)

## SARS-CoV-2 Vaccine Development & Implementation; Scenarios, Options, Key Decisions

Oct 1, 2020 • [The DELVE Initiative](#)

*This paper has drawn on evidence available up to 25th September 2020. Further evidence on this topic is constantly published and DELVE will continue to develop this report as it becomes available. This independent overview of the science has been provided in good faith by subject experts. DELVE and the Royal Society accept no legal liability for decisions made based on this evidence.*


### Summary

The SARS-CoV-2 pandemic has led to a global effort to develop, test, manufacture and distribute effective vaccines at unprecedented speed. There are currently over 200 vaccine candidates in development and the results of initial large-scale trials are expected soon; however, to deliver a successful vaccination programme, many challenges remain. This report discusses the key issues involved in developing, evaluating, manufacturing and distributing a vaccine for COVID-19, the impact of those challenges and future strategies to mitigate their effects.

# Different Border Status



Complete border closure to all short-term travelers, all incoming residents subject to quarantine-test protocols



Bilateral green lane arrangements for business and essential travel not including mass market tourism, all incoming travelers subject to some quarantine-test protocols with restricted itinerary



Multi- or bi-lateral travel bubble arrangements between selected countries, all incoming travelers subject to test protocols with no quarantine and unrestricted itinerary

# Current Evidence Suggests...

- Controlled-facility 14D quarantine protocol **safest but most disruptive** for border reopening
- Incubation period average **5-6 days**, observed up to **14 days**
- Pre-departure testing to minimize risk of infected travelers
- Infection on planes possible, but unlikely
  - HEPA, high air change rate
  - Frequent cleaning and disinfection of high touch points (lavatories)
  - Mask wearing, hand hygiene
- On-arrival testing as second net to catch infected travelers

# Known Challenges

- RT-PCR tests versus Antigen Rapid tests? **Or to focus on the characteristics of tests according to incoming risk?**
- Accrediting cross-border testing protocols
- Assessing importation risk:
  - Situation at originating city, including implemented public health measures to monitor and control
  - Volume of travelers
  - Testing sensitivity and specificity (impact false +ves, -ves)

# For Discussion

- Different countries at different stages of outbreak, how to adopt nuanced approach towards border reopening
- Characteristics of tests to facilitate border reopening, including use of pre-departure, on- and post-arrival (repeated) testing strategies
- Framework, standards and accreditation for border reopening between (some) countries

# Opening Remarks

## Risk Assessment for Travel

**Professor David Heymann**  
Chair, WHO Strategic and Technical Advisory Group  
for Infectious Hazards (STAG-IH)

